Generate the First Clinical Evidence With the Right Safety Architecture
Bioexcel supports innovative medical device manufacturers as they move from preclinical evidence into first clinical use and early feasibility evaluation.
Our approach connects device risk, procedure complexity, investigator expertise, staged enrollment, safety oversight, EDC, biostatistics and regulatory clinical strategy.
Does Bioexcel Support First-in-Human Medical Device Studies?
Yes. Bioexcel supports first-in-human and early feasibility medical device studies from evidence strategy and protocol development through site feasibility, safety planning, monitoring, EDC, data management, biostatistics and final clinical reporting.
Bioexcel Lifesciences & Research LLP supports first-in-human and early feasibility medical device studies, including clinical strategy, protocol development, site feasibility, safety oversight, monitoring, EDC, biostatistics and final clinical reporting.
The Objective Is Not to Prove Everything at Once
A first-in-human study may aim to answer:
- Can the device be used as intended?
- Can the procedure be performed safely?
- Are there unexpected device-related risks?
- Is device deployment technically feasible?
- Does the device perform as expected?
- Are modifications required?
- What endpoints are practical?
- What follow-up is needed?
- What should change before a pivotal study?
The study should remain focused on early learning and controlled risk exposure.
Related, but Not Always Identical
First-in-Human
Typically represents the earliest human use of a new device or technology.
- Initial safety
- Technical feasibility
- Procedural feasibility
- Unexpected device effects
Early Feasibility
May include additional early clinical experience after the first cases.
- Refined procedural technique
- Device-performance trends
- Endpoint feasibility
- Study-design refinement
- Preparatory evidence for larger studies
From Preclinical Evidence to Pivotal Readiness
Preclinical Evidence Review
- Bench testing
- Biocompatibility
- Animal data
- Risk Management
- Device verification/validation
- Existing clinical evidence
Output: Early Clinical Readiness Assessment
Residual Clinical Questions
- Safety uncertainties
- Device-performance uncertainties
- Procedure-related uncertainties
- User-related risks
Output: FIH Evidence Questions
Study Architecture
- Population
- Site
- Investigator
- Sample size
- Endpoints
- Follow-up
- Safety rules
Output: FIH / EFS Strategy
Protocol / CIP
- Study methodology
- Safety surveillance
- Enrollment sequence
- Device procedures
- Stopping rules
Output: Clinical Investigation Plan
Specialist Site Selection
- Highly experienced investigator
- Appropriate infrastructure
- Emergency support
- Device/procedure expertise
Output: Qualified Site
Initial Enrollment
- Sentinel patient
- Small initial cohort
- Staged enrollment
Output: Initial Safety Data
Safety Review
- Events
- Device performance
- Procedure issues
- Device deficiencies
Output: Continue / Modify / Pause Decision
Expanded Early Enrollment
- Continue according to predefined rules
Output: Early Feasibility Dataset
Pivotal Readiness
- Device modifications
- Endpoint selection
- Sample-size assumptions
- Investigator learning
- Pivotal design
Output: Next Clinical Development Strategy
What Is a First-in-Human Medical Device Study?
A first-in-human medical device study is an early clinical investigation in which a device is evaluated in humans for the first time or during very limited early clinical use, primarily to assess initial safety, technical feasibility, procedural feasibility and early performance.
What FIH services does Bioexcel provide?
Bioexcel supports early clinical strategy, CIP/protocol development, specialist site feasibility, safety planning, monitoring, EDC, biostatistics and Clinical Investigation Report preparation for first-in-human and early feasibility medical device studies.
Can Bioexcel support high-risk devices?
Bioexcel can support clinical evidence planning and operations for complex and higher-risk medical devices, subject to device-specific feasibility, regulatory requirements and appropriate investigator/site capability.
Can Bioexcel help plan the pivotal study after FIH?
Yes. Early clinical findings can be used to refine endpoints, sample-size assumptions, follow-up, training and the subsequent pivotal clinical strategy.
Is the Device Ready for Human Use?
Before protocol finalization, Bioexcel can review available information such as:
- Device description
- Intended purpose
- Bench verification
- Validation
- Biocompatibility
- Animal data
- Risk Management
- Usability/human factors
- Manufacturing readiness
- Existing clinical evidence
Output
Early Clinical Readiness & Evidence Gap Assessment
Safety Should Be Designed Into the Study
Potential components:
- Conservative eligibility
- Specialist investigators
- Controlled initial enrollment
- Sentinel cases
- Staged enrollment
- Enhanced observation
- Predefined stopping criteria
- Safety review before expansion
- Emergency management plan
- Close device deficiency tracking
Start With Controlled Exposure Where Appropriate
This can reduce uncontrolled exposure while early safety information is being collected.
Sentinel enrollment is not mandatory for every early feasibility study. It should be scientifically and clinically justified.
Expand Only After Reviewing Early Experience
Stage 1
2–3 participants
→ Safety review
Stage 2
Additional participants
→ Safety + feasibility review
Stage 3
Remaining cohort
Depends On
Can Bioexcel Support Staged or Sentinel Enrollment?
Yes. Where appropriate for the device and risk profile, Bioexcel can incorporate staged or sentinel enrollment into the clinical investigation plan together with predefined safety-review and continuation criteria.
Define What Happens if an Unexpected Safety Signal Appears
Potential criteria may involve:
- Unexpected serious device effect
- Device failure
- Procedure-related serious event
- Excessive adverse-event frequency
- Unexpected device deficiency
- Technical failure
- Unanticipated clinical risk
Stopping rules should be device-specific and clinically meaningful.
Early Data Need Prompt Clinical Review
Potential review inputs:
- Adverse events
- Serious adverse events
- Device-related events
- Procedure-related events
- Device deficiencies
- Technical success
- Imaging
- Laboratory results
- Investigator observations
Review Output
Independent Safety Review Where Appropriate
Depending on risk and study design, a sponsor may consider an independent safety-review mechanism. Potential responsibilities:
- Periodic safety review
- Review of predefined events
- Recommendation on enrollment progression
- Review after sentinel cohort
- Evaluation of stopping criteria
Clinical Oversight Beyond Routine CRA Monitoring
Medical monitoring may support:
- Safety-event review
- Investigator discussion
- Event relatedness
- Serious-event escalation
- Clinical interpretation
- Emerging safety signal review
Where required, roles should be defined before study initiation.
The Investigator Is Critical in Early Device Development
Ideal attributes may include:
- Deep therapeutic expertise
- High procedure volume
- Experience with similar technologies
- Ability to manage complications
- Research experience
- Commitment to protocol
- Availability for intensive early follow-up
Can Bioexcel Identify Investigators for First-in-Human Studies?
Yes. Bioexcel can assess specialist investigators and hospitals based on procedure expertise, device experience, clinical infrastructure, complication-management capability and research readiness.
Early Studies Need the Right Clinical Environment
Cardiovascular
- Cath lab
- Cardiac surgery backup
- ICU
- Imaging
Implantable / Surgical
- Operating theatre
- Anesthesia
- ICU
- Imaging
- Emergency surgery capability
Digital / Robotic
- Required system infrastructure
- Trained technical team
- Appropriate procedure setting
Feasibility Should Be More Selective Than for Routine Studies
Assess:
- Investigator expertise
- Relevant procedure volume
- Complex-case experience
- Emergency support
- Device/procedure learning curve
- Clinical research infrastructure
- Monitoring access
- Follow-up capability
Already Have the Investigator?
Where a sponsor has identified a specialist site, Bioexcel can support:
- Readiness assessment
- Site qualification
- Ethics / regulatory start-up
- Study initiation
- Monitoring
- Data
- Statistics
- Reporting
Can Bioexcel Work With a Sponsor-Selected FIH Investigator?
Yes. Bioexcel can evaluate and operationally support sponsor-selected investigators and hospitals where they meet the clinical, infrastructure and study requirements.
The Protocol Should Reflect Early Clinical Uncertainty
Potential content:
- Device rationale
- Preclinical evidence
- Initial risk assessment
- Study objective
- Enrollment sequence
- Safety endpoints
- Technical endpoints
- Stopping rules
- Device deficiencies
- Follow-up
- Safety review
- Data management
- Statistical methodology
Focus on Safety and Feasibility First
Safety
- Serious adverse events
- Device-related adverse events
- Procedure-related adverse events
- Mortality where relevant
- Reintervention
- Device deficiency
Technical Feasibility
- Successful deployment
- Device placement
- Device retrieval where relevant
- Device function
Procedural Feasibility
- Procedure completion
- Procedure time
- Conversion
- Technical complications
Early Performance
- Initial functional result
- Imaging outcome
- Clinical performance
Early Studies May Explore Benefit Without Being Powered to Prove It
Potential exploratory measures:
- Symptom change
- Functional improvement
- Imaging outcomes
- Quality of life
- Physiological measures
These may help design the pivotal study but should not be overinterpreted in a small early feasibility cohort.
FIH Studies Are Usually About Learning, Not Large Confirmatory Hypotheses
Sample size may depend on:
- Device risk
- Early safety objective
- Feasibility objective
- Expected event frequency
- Regulatory strategy
- Available preclinical evidence
- Staged enrollment
How Is Sample Size Determined for a First-in-Human Medical Device Study?
FIH sample size is typically justified according to the early safety and feasibility objectives, device risk, expected event profile, staged enrollment strategy and amount of preclinical evidence, rather than using the same assumptions as a large confirmatory pivotal trial.
Early Data May Inform Enrollment Progression
Where appropriate, interim review can assess:
- Safety
- Device success
- Procedure success
- Device deficiencies
- Unexpected events
The review should follow predefined criteria.
Every Early Device Issue Matters
Categories
- Deployment problem
- Breakage
- Software error
- Device malfunction
- Packaging issue
- Sizing issue
- Delivery-system issue
- Unexpected performance problem
Can Influence
- Device redesign
- Training
- Protocol update
- Risk Management
- Pivotal-study design
Operator Experience May Influence Early Outcomes
- Procedure time
- Deployment success
- Device handling
- Complications
- Early vs later cases
The FIH study may help define training requirements for subsequent sites.
Standardize Clinical Use Before the First Case
Training may address:
- Intended device use
- Procedure steps
- Device preparation
- Deployment
- Troubleshooting
- Device accountability
- Safety reporting
- Device deficiency reporting
Sponsor and qualified technical personnel may participate as appropriate.
Intensive Early Oversight
Monitoring may prioritize:
- Consent
- Eligibility
- Procedure
- Primary safety outcomes
- Device deficiencies
- Serious events
- Follow-up
- Device accountability
Capture Early Clinical Experience Precisely
eCRFs may include:
- Screening
- Baseline
- Device/procedure
- Technical success
- Safety
- Device deficiencies
- Imaging
- Follow-up
- Reintervention
- Protocol deviations
Early Data Should Not Sit Unreviewed for Weeks
This enables early clinical learning to inform the next participant or cohort.
Statistics for Early Feasibility
Potential analyses:
- Descriptive safety
- Event rates
- Confidence intervals
- Device success
- Technical success
- Procedural success
- Individual patient profiles
- Exploratory outcome trends
For small studies, excessive hypothesis testing should be avoided.
Document What Was Learned, Not Just What Happened
Final reporting should address:
- Study conduct
- Enrollment
- Safety
- Device performance
- Device deficiencies
- Procedure
- Early clinical outcomes
- Protocol deviations
- Limitations
- Clinical interpretation
- Implications for next study
Early Human Data Should Feed Back Into Risk Management
Potential Outcomes
FIH Data May Lead to Device Refinement
Possible learnings:
- Device sizing
- Delivery
- User interface
- Procedure steps
- Implant positioning
- Software behavior
- Training
Any Modification Should Be Evaluated for Impact On
Use Early Feasibility Data to Design the Confirmatory Program
FIH / EFS can inform:
- Primary endpoint
- Safety benchmark
- Performance goal
- Sample-size assumptions
- Follow-up duration
- Investigator selection
- Training
- Device version
- Inclusion/exclusion criteria
How Does an Early Feasibility Study Support a Pivotal Study?
Early feasibility data can refine device design, investigator training, endpoints, expected event rates, sample-size assumptions, patient selection, follow-up and procedural methodology before a larger pivotal investigation is initiated.
Early Device Studies in India
Bioexcel can assess suitable India-based opportunities based on:
- Device type
- Regulatory pathway
- Investigator expertise
- Site infrastructure
- Patient population
- Risk profile
Can Bioexcel Support First-in-Human Medical Device Studies in India?
Bioexcel can assess and support suitable first-in-human and early feasibility programs in India, subject to the device, regulatory pathway, clinical risk and availability of appropriately qualified investigators and sites.
European Early Clinical Programs
Bioexcel can support European feasibility and operations through suitable local resources, subject to applicable country and regulatory requirements. Potential functions:
- Country feasibility
- Site identification
- Investigator assessment
- Monitoring
- Central data/statistics
Early Clinical Evidence for Complex Technologies
Relevant device categories may include:
The final strategy should remain device-specific.
One Team From First Protocol to Pivotal Planning
Already Have a Protocol or Site?
Bioexcel can provide individual functions such as:
- Protocol review
- FIH statistical review
- Site feasibility
- Monitoring
- EDC
- Medical monitoring coordination
- Biostatistics
- Final report
Why Innovators Use Bioexcel for Early Medical Device Studies
MedTech Specialization
Study architecture reflects device and procedure-specific risks.
Safety-First Design
Early enrollment and review can be built around controlled exposure.
Specialist Site Feasibility
Investigator expertise is prioritized.
Integrated Operations
Monitoring, EDC, safety and statistics are connected.
Clinical Development Continuity
The study is designed to inform the next clinical phase.
Flexible Support
Full-service or functional delivery.
First-in-Human & Early Feasibility Deliverables
Depending on scope:
- Early Clinical Readiness Assessment
- Clinical Evidence Gap Assessment
- Study synopsis
- CIP / protocol
- Safety architecture
- Stopping-rule framework
- Site Requirement Profile
- Site feasibility
- SIV documentation
- Monitoring Plan
- eCRF / EDC
- Data Management Plan
- SAP
- Interim outputs
- Monitoring reports
- Clinical Investigation Report
- Pivotal-development recommendations
Early Clinical Development in Practice
Implantable Cardiovascular Technology
Clinical Question: Initial safety + technical feasibility
Model: Small staged early clinical investigation — Bioexcel Scope: Strategy, site, protocol, monitoring, EDC, statistics and reporting
Surgical Technology
Clinical Question: Procedure feasibility and user learning
Study Focus: Technical success, procedure performance and safety
Frequently Asked Questions About First-in-Human Studies
Bioexcel supports first-in-human and early feasibility medical device programs from study strategy through clinical reporting, subject to device-specific feasibility and regulatory requirements.
Bioexcel helps MedTech innovators generate the first human evidence with a controlled, clinically focused pathway toward pivotal development.